Liver and biliary tract cancer trials in South Korea
77 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
- Where
- Seoul
- Age
- 18 years and over
- People
- 30 worldwide
- Run by
- Elevar Therapeutics
See details and how to joinNCT07359820 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Jongno -Gu, Seoul
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - No phaseTaking peopleDevelopment and Utilization of an Integrated Clinical Genomic Database
- Where
- Seoul
- People
- 118,750
- Run by
- Samsung Medical Center
See details and how to joinNCT07911267 - Phase 1/2Taking peopleA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Where
- Seoul
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06428409 · EU 2023-508703-21-00 - Phase 1/2Taking peopleBOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
- Where
- Goyang, Seoul
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00 - Phase 3Taking peopleEfficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Where
- Bundang-Gu, Seongnam-Si, Busan, Ilsandong-gu, Goyang-si, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 286 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06282575 · EU 2023-508219-21-00 - Phase 1Taking peopleA Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Where
- Busan, Seongnam, Seoul
- Age
- 18 years and over
- People
- 158 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT06600321 · EU 2024-519499-22-00 - Phase 1/2Taking peopleA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Where
- Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 198 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07291076 · EU 2025-523602-33-00 - Phase 2Taking peoplePULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
- Where
- Seoul
- Age
- 19 years and over
- People
- 38
- Run by
- Samsung Medical Center
See details and how to joinNCT07884877 - Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Busan, Cheongju-si, Jinju, Seoul
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 1/2Taking peopleFirst in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Where
- Seoul
- Age
- 18 years and over
- People
- 304 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06795022 · EU 2024-516698-56-00 - Phase 1Taking peopleSafety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- Where
- Seoul
- Age
- 18 years and over
- People
- 125 worldwide
- Run by
- Tyra Biosciences, Inc
See details and how to joinNCT06915753 - Phase 3Taking peoplePhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Where
- Busan, Gyeonggi-do, Hwasun-gun, Seongnam-si, Seoul
- Age
- 18 years to 99 years
- People
- 620 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06467357 · EU 2023-508057-19-00 - Phase 3Taking peoplePhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Where
- Busan, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 1,220 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06921785 · EU 2024-518210-81-00 - No phaseNot yet taking people in South KoreaBile ctDNA Genomic Profiling and Concordance With Tumor Tissue in Biliary Tract Cancer
- Where
- Seongnam-si
- Age
- 19 years and over
- People
- 100
- Run by
- CHA University
See details and how to joinNCT07830628 - No phaseTaking peopleImjudo & Imfinzi PMS
- Where
- Busan, Goyang, Seongnam, Seoul, Suwon
- People
- 246
- Run by
- AstraZeneca
See details and how to joinNCT06544629 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Seoul
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 2Taking peopleAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Where
- Gyeonggi-do, Seoul
- Age
- 18 years and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06219941 · EU 2023-508275-37-00 - Phase 3Taking peopleA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Where
- Busan, Daegu, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 1,100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07221253 · EU 2025-523085-24-00 - Phase 1/2Taking peopleClinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- Where
- Cheongju-si, Incheon, Jinju, Seongnam-si, Seoul, Suwon, Ulsan
- Age
- 18 years and over
- People
- 147 worldwide
- Run by
- Yuhan Corporation
See details and how to joinNCT05523947 - Phase 1Taking peopleA Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
- Where
- Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 40 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391670 · EU 2025-521639-34-00 - Phase 2Taking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Seoul
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - Phase 1/2Taking peopleA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Where
- BundangGu SeongnamSi, Cheongju-si, GangnamGu, SeodaemunGu, Seongnam-si, Seoul, SongpaGu
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00 - Phase 1Taking peopleSKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- SK Life Science, Inc.
See details and how to joinNCT07812805 - Phase 2Taking peopleStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
- Where
- Busan, Daegu, Jinju, Seongnam, Seoul
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT05727176 · EU 2023-503665-39-00